Kuhnil Pharm transfers Omacor technology back to original Italian pharma
Kuhnil Pharm(CEO Young-Joong Kim) signed a license-out and export agreement of ‘Rosumega SC’ with Italian Società Prodotti Antibiotici(hereinafter referring to S.p.A) on 10 May.
Under the agreement, Kuhnil Pharm will distribute finished products, and S.p.A will take charge in acquiring approval ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
